Compare ASYS & OABI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ASYS | OABI |
|---|---|---|
| Founded | 1981 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 268.2M | 294.3M |
| IPO Year | 2006 | 2021 |
| Metric | ASYS | OABI |
|---|---|---|
| Price | $15.40 | $3.38 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $4.50 |
| AVG Volume (30 Days) | 351.4K | ★ 505.8K |
| Earning Date | 05-07-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 6.56 |
| EPS | ★ 0.19 | N/A |
| Revenue | ★ $79,364,000.00 | $18,666,000.00 |
| Revenue This Year | $2.82 | $52.42 |
| Revenue Next Year | $18.75 | $64.69 |
| P/E Ratio | $79.76 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $4.60 | $1.32 |
| 52 Week High | $25.71 | $3.43 |
| Indicator | ASYS | OABI |
|---|---|---|
| Relative Strength Index (RSI) | 43.41 | 84.51 |
| Support Level | $10.84 | $1.84 |
| Resistance Level | $17.83 | N/A |
| Average True Range (ATR) | 1.08 | 0.19 |
| MACD | 0.09 | 0.17 |
| Stochastic Oscillator | 41.29 | 94.83 |
Amtech Systems Inc provides equipment, consumables and services for semiconductor device packaging, wafer production and device fabrication. Its products are used to fabricate and package GPUs for AI applications, SiC and Si power devices, and other optical, analog and digital devices, and are sold to semiconductor packaging, electronic assembly and device fabrication companies. It operates through two segments: Thermal Processing Solutions, which includes conveyorized reflow equipment, high-temperature conveyorized furnaces and diffusion furnaces with maximum revenue; and Semiconductor Fabrication Solutions, which includes consumables, equipment and services for wafer polishing, dicing and cleaning. The majority of revenue is derived from the United States.
OmniAb Inc licenses discovery research technology to pharmaceutical and biotech companies and academic institutions to enable the discovery of next-generation therapeutics. Its technology platform creates and screens diverse antibody repertoires and is designed to quickly identify optimal antibodies and other target-binding proteins for its partners' drug development efforts. At the heart of the OmniAb platform is what it calls Biological Intelligence, which powers the immune systems of proprietary, engineered transgenic animals to create optimized antibody candidates for human therapeutics.